Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 76Neoplasm Metastasis 12Neoplasms 10Neoplasms by Site 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Breast Diseases 3Recurrence 2Kidney Neoplasms 2Endometrial Neoplasms 2Digestive System Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma 1

Interventions

Dexamethasone 64Lenalidomide 34pomalidomide 33Cyclophosphamide 33Rituximab 31Bortezomib 29venetoclax 27fludarabine 26Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 16Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Injections 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × palbociclib × Clear all
NCT06760637 2026-05-19

FourLight-3

Pfizer

Phase 3 Active not recruiting
1,035 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Ono Pharmaceutical Co., Ltd.

Phase 1 Active not recruiting
46 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡